Sandoz
Clinical trials sponsored by Sandoz, explained in plain language.
-
New biosimilar drug tested against established cancer treatment
Disease control TerminatedThis study aims to see if a new, potentially more affordable version of the cancer drug pembrolizumab (called GME751) works as well and is as safe as the original drug. It will involve 218 adults with untreated metastatic non-small cell lung cancer. Participants will receive eith…
Phase: PHASE3 • Sponsor: Sandoz • Aim: Disease control
Last updated Apr 04, 2026 04:51 UTC
-
Tracking Real-Life use of a common IBD treatment
Disease control OngoingThis study aims to see how long patients with Crohn's disease or ulcerative colitis (collectively called IBD) continue using the biosimilar medication Hyrimoz in real-world doctor's offices. Researchers will follow over 500 patients for up to a year to see if they stay on the tre…
Sponsor: Sandoz • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New biosimilar drug tested to keep melanoma at bay after surgery
Disease control OngoingThis study aims to see if a new, proposed biosimilar drug called GME751 works similarly to the established drug Keytruda (pembrolizumab). It involves 322 adults with stage II or III melanoma who have had their cancer surgically removed. The goal is to prevent the cancer from retu…
Phase: PHASE1 • Sponsor: Sandoz • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC